Public research summary

VCEL Stock Analysis: Vericel Corporation

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a huma

Data through Oct 2, 2026
Latest close
$40.15
20-day change
+0.00%
Trend state
NEUTRAL
Classification
Healthcare · Biotechnology

Market context

Vericel Corporation moved +0.00% over the latest 20-session window. BullRecon currently classifies the broader setup as NEUTRAL.

Latest report

The latest cached company filing period (FY2025 · $276.3M revenue · $16.5M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.

Six-dimension read

Health is currently the strongest dimension at 5.8/6, while Value is the lowest at 3.1/6. Scores are comparative research signals, not forecasts.

Value 3.1/6
Growth 5.0/6
Quality 5.3/6
Profitability 3.8/6
Health 5.8/6
Future 4.2/6
Built from cached market data, company filings and transparent rule-based calculations. Automated research is informational and is not investment advice.

Loading the interactive report and checking your access…